Cumberland Pharma sells commercial products to Apotex for $100M, retains pipeline

CUMBERLAND PHARMACEUTICALS INC

Apotex acquires six FDA-approved brands (Acetadote, Caldolor, Kristalose, Sancuso, Vaprisol, Vibativ) for $100M cash.
Cumberland retains ifetroban pipeline (DMD, SSc, IPF) and majority stake in CETI.
Deal requires shareholder approval; directors & officers holding ≈41% of shares signed voting agreements to support.
Either party may owe $4M termination fee under conditions; closing targeted by August 20, 2026.
Board and financial advisor VelocityHealth opined $100M consideration fair and reasonable to Cumberland.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

CUMBERLAND PHARMACEUTICALS INC entered into Asset Purchase Agreement with Apotex Inc. valued at $100,000,000 (effective 2026-04-22).

Action: entry
Agreement: asset purchase
Counterparty: Apotex Inc.
Value: $100,000,000
Effective: 2026-04-22

Exact text from the filing

On April 22, 2026, Cumberland Pharmaceuticals Inc. (the “ Company ” or “ Cumberland ”) entered into a strategic transaction (the “ Transaction ”) to integrate its commercial products with the U.S. branded business of an affiliate of Apotex Inc., a corporation incorporated under the laws of the Province of Ontario (“ Apotex ”), in exchange for $100,000,000 payable at the closing of the Transaction.

View on SEC.gov

Browse all material agreements →

CUMBERLAND PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001104659-26-047335

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.